Expression of candidate ivermectin resistance genes in the scabies mite, Sarcoptes scabiei
Kate Mounsey, Debra Holt, James McCarthy, Bart J. Currie, Shelley F. Walton
Abstract
Open-access reader
Kate Mounsey, Debra Holt, James McCarthy, Bart J. Currie, Shelley F. Walton
Abstract
Open-access reader
Oral ivermectin (IVM) is increasingly used to treat ordinary scabies, and is the drug of choice in northern Australia for hyper-infested (crusted) scabies. Reports of ivermectin resistance in crusted scabies raise concerns regarding the sustainability of this relatively new drug for scabies. In light of increasing ivermectin use, and its likely incorporation into community mass treatment programs, it is critical to define mechanisms of ivermectin resistance in scabies mites.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Oral ivermectin (IVM) is increasingly used to treat ordinary scabies, and is the drug of choice in northern Australia for hyper-infested (crusted) scabies. Reports of ivermectin resistance in crusted scabies raise concerns regarding the sustainability of this relatively new drug for scabies. In light of increasing ivermectin use, and its likely incorporation into community mass treatment programs, it is critical to define mechanisms of ivermectin resistance in scabies mites.
Key concepts: Ivermectin, Scabies, Sarcoptes scabiei, Mite, Biology, Drug resistance, Veterinary medicine, Dermatology